Influence of SLCO1B1 and CYP2C8gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers

Table 4 Rosiglitazone pharmacokinetic parameters by CYP2C8 genotype

Pharmacokinetic parameter	CYP2C81/1 n= 19	CYP2C81/3 n= 7	p value
AUC_0-∞ (ng*h/ml)	1914 ± 469 (1688, 2140)	1352 ± 300 (1075, 1629)	0.002
C1/F (ml/h)	2212 ± 550 (1947, 2477)	3072 ± 602 (2516, 3629)	0.008
CL/F/kg (ml/h/kg)	33.9 ± 7.1 (30.4, 37.3)	45.9 ± 11 (35.7, 56)	0.03
t_1/2 (h)	4.0 ± 0.8 (3.7, 4.4)	3.5 ± 0.7 (2.9, 4.1)	0.09
C_max (ng/ml)	402 ± 115 (347, 458)	317 ± 56 (266, 369)	0.02
T_max (h)	1.0 ± 0.5 (0.7, 1.2)	0.7 ± 0.3 (0.5, 1.0)	0.13

Data are presented as mean ± SD, along with 95% confidence intervals. Abbreviations: AUC, area under the plasma concentration-time curve; CL/F, apparent oral clearance; CL/F/kg, weight-adjusted oral clearance; t_1/2, half-life; C_max, maximum plasma concentration; T_max, time to maximum plasma concentration.

ISSN: 1479-7364